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Abstract
Background and Objective The Ministry of Health (MoH)
leads and organizes health policy in Kosovo, which
includes procurement and provision of medicines, includ-
ing anti-cancer medicines, which compose a special group
of medicines. However, there has been limited analysis of
the utilization and expenditure on anti-cancer medicines in
Kosovo; consequently, the objective of this study is to
undertake research to provide future guidance on the use of
anti-cancer medicines.
Method National drug utilization data is available in
Kosovo. Utilization and expenditure on anti-cancer
medicines [Anatomical Therapeutic Chemical (ATC) code
L], initially from 2011 to 2013, especially for anti-cancer
medicines on the essential medicines list was analysed
from national data. In addition, current systems for
procuring and managing anti-cancer medicines in Kosovo
was documented.
Results There was appreciable variability in the utilization
of anti-cancer medicines over the years, with low or limited
use of some anti-cancer medicines on the Essential Medi-
cine List. This is a concern in view of their essential
medicine status. From 2011 to 2013, €16.49 million was
spent on anti-cancer medicines (ATC L). The process of
selection of new medicines begins with suggestions from
doctors at the University Clinical Centre in Kosovo.
Conclusion The analysis has shown appreciable variation
with current utilization patterns for anti-cancer medicines
in Kosovo. This needs to be addressed as part of improving
the drug management process to optimize patient care
within available resources. Future years and reforms need
to be assessed to improve current utilization and expendi-
ture patterns.
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Key points for decision makers
There are considerable discrepancies regarding the
current utilization patterns of anti-cancer medicines
in Kosovo as there was no utilization of some anti-
cancer medicines considered vital, essential, or
necessary based on the essential medicine list.
Only a few anti-cancer medicines have very high
expenditure; however, there are variations in their
use across the years.
The MoH should carefully consider introducing
updated processes for the selection and pricing for
new medicines.
1 Introduction
For many years health authorities across the world have
published annual medicine consumption data, which have
been widely used among key stakeholder groups. This
includes monitoring the influence of ongoing reforms and
initiatives, and using the outputs to plan future initiatives
and budgets [1–4]. This is particularly the case in a number
of European countries where health authorities and health
insurance agencies strive towards universal access within
finite budgets.
In Kosovo currently, the Ministry of Health (MoH) leads
and organizes health policy processes, achieving many of
its objectives through subordinate institutions such as the
Kosovo Medicines Agency (KMA). The KMA is respon-
sible for the public health of the population by ensuring
drug safety, quality, and efficacy, as well as overseeing the
importation of medicines into Kosovo and conducting
analyses of overall drug consumption.
New anti-cancer medicines are typically seen as a spe-
cial group of medicines as this is an emotive area, generally
leading to greater leeway for pricing considerations and
funding than for other medicines, such as those for car-
diovascular diseases or mental health [5, 6]. There is
growing concern worldwide regarding these drugs, with
prices of cancer medicines rising up to tenfold during the
past 10 years in some countries despite often limited health
gains [7, 8]. This causes particular concern in countries
with fixed budgets, with the resultant opportunity cost
implications for patients with cancer and other diseases
[9, 10] leading to prescribing restrictions and other mea-
sures to limit their use and reduce the prices of new cancer
medicines [11, 12]. Consequently, in European countries
with appreciable pressure on resources such as Kosovo,
there is an imperative need to review current utilization and
expenditure patterns for cancer medicines, as well as the
selection process for new anti-cancer medicines, to make
sure available resources are being optimally used. In recent
years the prevalence of cancers in Kosovo has been
increasing [13]. In 2015, the greatest incidence was for
melanomas and other malignant neoplasms of the skin (411
new cases), breast neoplasms (274 new cases), malignant
tumors of the digestive system (262 new cases), and
malignant tumors of the genital organs (257 new cases).
Together, these made up 1204 of the total 1751 new cases
of cancer in Kosovo 2015 [14].
In addition, reports following MoH workshops have
suggested that in 2017 there is an increasing trend in the
total number of cancers in Kosovo, and that some of these
cases are due to better diagnostics and awareness cam-
paigns leading to more patients being diagnosed earlier (A.
Jakupi, unpublished data).
The Kosovo University Clinical Center Service
(KUCCS) is a key institution in Kosovo’s health system as
all of the hospitals that offer secondary and tertiary-level
care, such as the University Clinical Centre of Kosovo
(UCCK), function within its framework. The Oncology
Institute operates within the UCCK and KUCCS frame-
work and, along with other institutes, also deals with the
overall management of cancer patients in Kosovo, includ-
ing chemotherapy and radiotherapy. The supply of
medicines in UCCK is undertaken through the central
pharmacy, which supplies all clinics.
However, little is known generally about medicine
consumption in Kosovo including anti-cancer medicines,
although drug consumption data for 2011–2013 were
published by the KMA in 2014. In addition, the procure-
ment process of the MoH is now centralized, as recom-
mended by the World Health Organization (WHO) and the
World Bank [15]. In contrast, the other processes have
been decentralized since 2015 as every hospital, through its
own structures, is now responsible for the planning,
selection, and ordering of medicines and equipment.
The current selection process to update the oncology
medicine list begins with physicians, in this case those in
the Institute of Oncology. The list and suggested changes
are subsequently reviewed by the head of the clinic, the
central pharmacy director, and the general director of the
hospital. After this process, the suggested updated list is
submitted to the professional working group of the MoH
for the final review and approval by the Minister of Health.
Figure 1 illustrates this process.
Once the list is signed by the Minister, the second part of
the drug management process proceeds, i.e., the procure-
ment of the medicines from the agreed essential medicines
list intended for hospital use. This process is carried out in
a centralized way by the MoH for all hospitals in Kosovo,
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with the system being transparent to help reduce possible
corruption [17]. After this, the process is continued with
the distribution to the central pharmacies (of each hospital),
from where available medicines are supplied to all of the
clinics. This process is carried out under the supervision of
the chief pharmacists of the hospitals, ready for clinicians
to use the oncology medicines in their clinics.
Consequently, the aim of this paper is to critically
review the utilization of and expenditure on anti-cancer
medicines in Kosovo, including the selection processes for
listing medicines in Kosovo. The findings are then used to
suggest future strategies in Kosovo to improve the use of
cancer medicines within available resources, building on
the expertise of the co-authors working with health
authorities across Europe, including Kosovo and wider, and
their networks.
2 Methodology
The drug utilization and expenditure data were obtained
from the MoH and the wholesale drug suppliers, similar to
those for other disease areas [18]. Due to the lack of
electronic reporting systems currently in Kosovo, unlike in
the Nordic countries and Scotland as well as other central
and eastern European countries [19–25], these data have to
be manually recorded. Kosovo’s pharmaceutical sector has
two main parts: the private sector where drug dispensing
for ambulatory care patients is achieved through the 621
pharmacies in the country [26]; and the public sector,
which includes hospitals supplied with medicines from the
Essential Medicines List, previously procured through the
central procurement of the MoH—these medicines are
provided only to hospitalized patients.
The utilization of anti-cancer drugs in Kosovo is based
on 58 molecules currently available in the Essential Med-
icine List (EML) according to their generic name or
International Nonproprietary Name (INN) [27] each cal-
endar year. For this initial study, data were collected from
wholesalers for the 2011–2013 period [28], as all of the
licensed wholesalers in Kosovo are obliged to make an
application to the KMA for all medicines they import,
which includes their INN name, brand (originator) name,
dosage form, strength, serial number, and quantity. The
reason for the 3-year period was that this was the first
official publication by the KMA on drug consumption in
Kosovo, providing a basis for future reporting [29]. The
methodology is based on the Anatomical Therapeutic
Chemical (ATC) drug classification methodology, which is
internationally recognized as the standard for undertaking
drug utilization research [30–34]. Datasets recorded
including the dose, strength, unit quantity, per unit, and
overall expenditure for each anti-cancer medicine. Pricing
data came from the MoH [29]. Expenditure was recorded in
euros as this is the official currency in Kosovo.
Other sources of drug consumption data include the
hospital selection and planning of the medicines process,
with data collected from the working group in the MoH
[Ministers decision 60/13 (16 April 2013) and 74/13 (5
June 2013)]. This group has the duty of categorizing the
various medicines, including cancer medicines, into VEN
(Vital, Essential, Necessary) categories as per WHO rec-
ommendations [35]; one of the authors (AJ) is a consultant
to the MoH leading the group for this type of analysis. The
data were further analyzed and interpreted for this publi-
cation. The data were collected in Microsoft Excel (Mi-
crosoft Corp., Redmond, WA, USA) and subsequently
converted into informative figures and tables.
Fig. 1 Selection process for
updating the Essential
Medicines List for new anti-
cancer medicines (based on
Quick et al. [16])
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The analysis of oncology medicines is based on the
essential list of cancer medicines approved by the MoH
(which is also public). The list of medicines is broken down
by overall expenditure during the study period and then by
overall class and year before concentrating on the anti-
cancer medicines with the highest expenditures. Anti-can-
cer medicines are classified by VEN as per the MoH
working group. This is similar to the VEN analysis and
ABC analysis (typically Class A medicines include
10–20% of the items under consideration but constitute
75–80% of total expenditure, Class B constitutes 10–20%
of the items under consideration but 15–20% of total
expenditure, and Class C constitutes the remaining items
but only 5–10% of total expenditure) methodology of the
WHO [16, 35, 36]. The analysis of the 15 anti-cancer
medicines with the highest expenditures uses different time
periods in view of the appreciable variation that can occur
across the years.
In accordance with the WHO ATC classification system,
the active substances were divided into different groups in
relation to the organ or system on which they act and their
therapeutic, pharmacological, and chemical properties
[30, 37]. Medicines are classified into groups at five dif-
ferent levels, including 14 main groups (first level), and
further divided into different pharmacological/therapeutic
subgroups (second level). The third and fourth levels are
the chemical/pharmacological/therapeutic subgroups and
the fifth level is the chemical substance. Analysis of
medicines according to their ATC classification is used for
comparative purposes across countries [38], provides an
overview, and shows trends in medicine utilization in
relation to the different therapeutic areas.
3 Results
In this analysis, according to the ATC Level 3, the L01X
subgroup (other neoplastic agents) of cancer medicines has
the greatest expenditure and they are also utilized more
than other anti-cancer medicine groups, followed by the
L03A group (immunostimulants) (Fig. 2).
From Fig. 3, it can be seen that only a few anti-cancer
medicines currently have high expenditures in Kosovo,
with expenditure on bevacizumab, rituximab, and the
interferons increasing but variable expenditure on trastu-
zumab. These anti-cancer medicines were chosen for
illustrative purposes to demonstrate the appreciable varia-
tion in expenditure that can occur between the years, as
well as the limited expenditure on certain proven anti-
cancer medicines on the list of 58 essential medicines
currently available. Analysis of the 15 highest expenditure
items (Fig. 4) gives us further details of key anti-cancer
medicines to concentrate on for future analysis. Figure 5
depicts the anti-cancer medicines with the lowest expen-
ditures in recent years, again providing baseline data for
future policies and guidelines.
Figures 4 and 5 show the total expenditure, and the VEN
categorization, for the various anti-cancer medicines being
utilised in Kosovo. They show that medicines that have a
low value per unit (ampoule), such as €2 or €3 per ampoule
or similar, did not appear to be ordered by the Oncology
Institute, whilst there was a tendency to procure higher-cost
medicines. Table 1 shows that the final 15 anti-cancer
medicines on the Kosovo EML, when sorted by expendi-
ture within a year, have zero orders, whilst the five prior
products at the end of the list amounted to €2572 in total—
less than the expenditure on two ampoules of the first anti-
cancer medicine on the list (Table 1).
Table 1 shows that eight medicines that are categorized
as vital, and comprise 13.7% of the essential list of anti-
cancer medicines, have not been ordered at all by the
competent authority. In addition, there are 15 molecules
that have not been ordered at all (from all three categories
of V, E, and N) that comprise 25.86% of the total oncology
list.
4 Discussion
We believe that there are interesting findings from this
study that can provide future direction to the authorities in
Kosovo. When comparing our findings with Norway, a
European country with one of the highest GDPs (gross
domestic product) per capita, versus Kosovo, with one of
the lowest, differences can be seen. This is especially
evident when comparing the L01X subgroup in 2013,
which makes up 61.8% of the ATC code L (ATC L) group
in Kosovo, while the same subgroup only constitutes 22%
of the ATC L group in Norway [39]. The L04A group
(immunosuppressants) comprised 55% of the total expen-
diture in Norway versus Kosovo where this same subgroup
constituted only 2% of the ATC L group in 2013.
The appreciable differences in the relative consumption
of anti-cancer medicines between countries may be regar-
ded as being attributable to a lack of available resources in
Kosovo or, alternatively, resources being wasted in one
country versus another. On the other hand, differences in
percentage utilization among specific medicines in an ATC
group across similar time periods, such as immunosup-
pressants, can be considered to be an indication that current
treatment patterns need to be further evaluated to optimize
care within finite resources. According to Fig. 5 and
Table 1, paclitaxel, which is included in two dosage forms
(30 and 100 mg) in the EML, is shown to have zero
orders—a medicine which now has quite a low acquisition
cost and significantly lower prices than other anti-cancer
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medicines currently being used for similiar indications. In
the taxanes group, docataxel and paclitaxel have been key
components of chemotherapy regimens since the 1990s,
and they are usually prescribed after anthracycline-based
chemotherapy [40]. The paper by Webber-Foster et al.
[40] does not specify which taxane is preferred since they
are considered to be similar in effectiveness, albeit with
differences in adverse effects and costs. More lives could
potentially be saved with paclitaxel but with higher costs
than docataxel [40], although this is not universal. The
WHO expert committee, for instance, concludes that both
taxanes should be available for breast cancer treatment.
This is because, at present, their use, based on available
evidence, is different according to specific subgroups of
patients and concomitant treatments. In addition, there are
no cost-effectiveness data currently available for different
settings, or for different outcomes, leading to both taxanes
currently being included in the latest WHO essential list
of medicines [41, 42]. A representative of the anthracy-
cline group, daunorubicin (ATC L01DB), also has zero
orders (Table 1); this is also a cause for concern. Such
discrepancues can also be noted for other medicines in
Table 1.
The inclusion of cancer medicines in the EML, and their
free availability in hospitals, has benefited a great number
of patients with cancer, as currently patients have to cover
the full cost of medicines in ambulatory care in Kosovo.
However, this will only continue if there is good use of
existing resources in hospitals to treat patients with cancer
through robust processes for pricing, reimbursing, and
funding of medicines, along with a robust process for
regularly monitoring their use against agreed guidance.
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Fig. 2 Expenditure on anti-cancer medicines in Kosovo 2011–2013.
L01A alkylating medicines, L01B antimetabolites, L01C plant alka-
loids and other natural products, L01D cytotoxic antibiotics and other
related substances, L01X other neoplastic agents including cisplatin,
carboplatin and rituximab, L02A hormones and related substances,
L02B hormone antagonists and other related substances, L03A
immunostimulants, L04A immunosuppressants, Y year (adapted from
Drug Consumption in Kosovo [29])
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Fig. 3 Breakdown of
individual anti-cancer
medicines by expenditure 2011
to 2013 (adapted from Drug
Consumption in Kosovo [29])
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Table 1 and Figs. 3, 4, 5 show that only a few anti-
cancer medicines have very high expenditure in Kosovo,
but there use varies across the years, causing concern
regarding the most effective use of limited resources. The
significant differences in the ordering of cancer medicines
such as bevacizumab, trastuzumab, and capecitabine sug-
gest current processes are not coordinated. In addition,
there currently appear to be different protocols for treat-
ment of different indications in Kosovo, causing confusion
(A. Jakupi, unpublished data). This has implications for
any treatment approach in hospitals in Kosovo. In addition,
13.7% of cancer medicines which were categorized as vital
(Table 1) had zero orders, which is a concern as these
medicines are regarded as very necessary. Similarly, 15
products from the essential list of anti-cancer medicines
(from the three categories of V, E, or N), or 25.86% of
these medicines, had zero orders (Fig. 5, Table 1). With
closer scrutiny (Table 1), it can be seen that the prices of
these products do not surpass €26 per ampoule, whilst
medicines costing more than €1000 per ampoule have
orders that in total make up the largest expenditures
(Figs. 3, 4).
As a result, we believe that competent authorities
nationally and in hospitals should review and update their
processes to make the selection and planning process
relating to anti-cancer medicines a continuous and robust
process that adheres to the regulations for essential
medicines and pharmacoeconomic analyses. This is cur-
rently not the case even with the new procurement process.
In addition, there should be regular monitoring of the use
of medicines and the expenditure on them in practice
against an agreed single guidance, rather than multiple
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(V) CALCIUM FOLINAT
(V) METHOTREXAT
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(V) VINCRISTINFig. 5 Analysis of the 20 anti-
cancer drugs annual orders with
the lowest expenditure
including VEN (vital, essential,
necessary) analysis between
2011 and 2013
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(N) PEMETREXEDFig. 4 Analysis of the 15 anti-
cancer drugs annual orders with
the highest monetary
expenditure including VEN
(vital, essential, necessary)
analysis between 2011 and 2013
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Table 1 Expenditure and VEN (vital, essential, necessary) analyses of anti-cancer medicines in Kosovo
No. Generic name Pharmaceutical form Dose and
volume
V E N 12-month
quantity
Price/unit
(€)
Expenditure
(€)
1 Trastuzumab Concentration per solution per infusion 440 mg V 1320 1550.00 2,046,000.0
2 Bevacizumab Concentration per solution per infusion 400 mg/
16 mL
E 6400 309.00 1,977,600.00
3 Imatinib mesylate Tablet 400 mg E 12,600 98.30 1,238,580.00
4 Rituximab Concentration per solution per infusion 500 mg E 600 1145.00 687,000.00
5 Capecitabine Tablet 500 mg V 210,000 2.33 489,300.00
6 Sorafemib Tablet 200 mg E 10,800 36.50 394,200.00
7 Erythropoetin beta Prefilled syringe 30,000 IU V 1800 165.00 297,000.00
8 Ibandronate Concentration per solution per infusion 6 mg V 2160 125.00 270,000.00
9 Pemetrexed Powder concentration per solution 500 mg N 240 990.00 237,600.00
10 Goserelin Prefilled syringe 10.8 mg V 480 302.00 144,960.00
11 Docetaxel Concentration and dilution per solution
per infusion
40 mg/mL,
2 mL
V 4800 23.73 113,904.00
12 Filgrastim Solution per infusion 48 MIU V 3000 36.00 108,000.00
13 Rituximab Concentration per solution per infusion 100 mg E 400 230.00 92,000.00
14 Temozolamide Capsules 250 mg V 1680 50.86 85,444.80
15 Pemetrexed Powder concentration per solution 100 mg N 240 220.00 52,800.00
16 Cisplatin Powder concentration per injection 50 mg V 3960 13.00 51,480.00
17 Anastrazole Tablet 1 mg V 60,000 0.82 49,200.00
18 Ibandronate Tablet 50 mg V 7392 6.00 44,352.00
19 Gemcitabine Powder concentration per solution 1000 mg V 1800 19.90 35,820.00
20 Carboplatin Solution per infusion 10 mg/mL,
45 mL
V 1400 24.50 34,300.00
21 Cyproterone acetate Tablet 50 mg V 39,600 0.77 30,492.00
22 Doxorubicin Powder concentration per injection 50 mg V 3480 8.20 28,536.00
23 Oxaliplatin Concentration per solution per infusion 100 mg V 1800 15.00 27,000.00
24 Gemcitabine Powder concentration per solution 200 mg V 3600 6.00 21,600.00
25 Interferon-a-2a Prefilled syringe 3 MIU/5 mL N 1560 13.50 21,060.00
26 Dacarbazine Powder concentration per solution per
infusion
200 mg V 900 22.66 20,394.00
27 Fludarabine Tablet 10 mg E 600 29.00 17,400.00
28 Bacillus Calmette-
Guerin
Powder concentration per solution 81–100 mg N 200 70.00 14,000.00
29 Doxorubicin Powder concentration per injection 10 mg V 2880 3.00 8640.00
30 Ifosfamide Powder concentration per injection 1 g V 420 18.90 7938.00
31 Etoposide Solution per infusion 100 mg V 1800 3.73 6714.00
32 Chlorambucil Tablet 2 mg N 600 10.00 6000.00
33 5-Fluorouracil Solution per injection 50 mg/mL,
10 mL
V 2000 2.56 5120.00
34 Tamoxifen Tablet 20 mg V 48,000 0.10 4656.00
35 Fludarabine Powder concentration per injection 50 mg E 120 30.00 3600.00
36 Mesna Tablet 400 mg V 840 3.90 3275.16
37 Vinblastine Solution per injection 1 mg/mL,
10 mL
V 340 5.88 1999.20
38 Hydroxycarbamide Capsules 500 mg N 10,000 0.15 1500.00
39 Tioguanine Tablet 40 mg N 200 2.50 500.00
40 Calcium folinate Solution per injection 10 mg/mL,
5 mL
V 80 4.20 336.00
41 Methotrexate Tablet 2.5 mg V 1500 0.13 195.00
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guidances, to improve future care efficiently, as seen in
other countries such as Sweden [2, 11, 43]. There are
serious concerns relating to different guidances from dif-
ferent national and international groups giving conflicting
advice [44] as this is not in the best interest of any key
stakeholder group.
Pharmacoeconomic analysis in accordance with Pallis
et al. [45] should help improve decision-making in Kosovo
in such a way that would optimize the use of already
limited resources dedicated to the treatment of cancer
patients. This is essential with limited resources as per the
concept of opportunity cost [9].
We accept that there are a number of limitations to this
study. This includes the fact that there is currently no
information on the extent to which people are travelling
from neighboring countries to Kosovo for treatment. There
is also no doubt that available databases contain incomplete
information as there is currently considerable reliance on
manually recorded information. However, we believe our
findings are robust, providing future direction to all key
stakeholder groups in Kosovo in this important disease
area.
5 Recommendations
In view of our findings, we believe that the MoH in Kosovo
should take a lead role in updating current regulations
regarding that the process of selection of new and existing
medicines and including/excluding medicines from the
essential list, including active disinvestment, where
appropriate. In addition, the MoH should clearly define the
use of and need for pharmacoeconomic analyses to aid
reimbursement and funding decisions, encourage the use of
drug utilization studies to monitor the use of anti-cancer
medicines in routine care, as well as update and consolidate
treatment protocols into a single source, replacing the
current confusion. Regularly monitoring the utilization and
expenditure on anti-cancer medicines will highlight if any
agreed essential medicines are currently not being used.
Key clinicians should be part of any guideline development
and monitoring processes in order to enhance their adher-
ence to jointly agreed medicines and their use, which has
worked well in other countries [46]. The MoH should also
separately look at its procurement process, including prices
for similar medicines in neighboring countries, to again
Table 1 continued
No. Generic name Pharmaceutical form Dose and
volume
V E N 12-month
quantity
Price/unit
(€)
Expenditure
(€)
42 Methotrexate Solution per injection 50 mg/mL,
1 mL
V 60 3.19 191.40
43 Asparaginase Solution per injection 10 MIU,
10 mL
36 2.00 72.00
44 Bleomycin Powder concentration per infusion 15 IU V 0 26.60
45 Citarabine Solution per injection 100 mg/mL,
1 mL
N 0 3.50
46 Cyclophosphamide Powder concentration per solution 200 mg V 0 2.59
47 Cyclophosphamide Powder concentration per solution 1000 mg V 0 5.69
48 Daunorubicin Powder concentration per injection 20 mg N 0 12.23
49 5-Fluorouracil Solution per injection 50 mg/mL,
5 mL
V 0 1.68
50 Irinotecan Concentration per solution per infusion 20 mg/mL,
5 mL
V 0 18.00
51 6-Mercaptopurine Tablet 50 mg N 0 1.50
52 Melphalan Tablet 2 mg N 600
53 Paclitaxel Concentration per solution per infusion 100 mg V 0 16.00
54 Paclitaxel Concentration per solution per infusion 30 mg V 0 6.30
55 Procarbazine Tablet 50 mg N 0
56 Sodium clodronate Capsules 800 mg N 0 3.94
57 Sodium clodronate Concentration per solution per infusion 60 mg/mL,
5 mL
N 0 15.86
58 Vincristine Solution per injection 1 mg/mL,
1 mL
V 0 8.50
Caps capsule, Conc concentration, Dil dilutant, E essential, Inf infusion, Inj injection, IU international units, mg milligram, ml millilitre, MIU
million internationalunits, N necessary, Plv pulvis – powder, Sol solution, Tbl tablet, VEN Vital – Essential - Necessary, V vital
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optimize the use of available resources. Pharmacoeco-
nomics, including value-based pricing, should be part of
this.
Furthermore, the MoH could also explore the potential
of delegating some of its responsibility to a working group,
which could include Drug and Therapy Committees, to
regularly monitor the prescription and consumption of
medicines in high-priority areas such as cancer. In this
way, the drug management cycle would be improved as all
parts of the chain would be more precisely monitored and
performed. The inclusion of electronic systems in the
future will further help with such processes. This will form
part of future research projects in Kosovo.
6 Conclusion
In this article we have shown discrepancies regarding
current procedures relating to the utilization of and
expenditure on anti-cancer medicines in Kosovo, including
no or limited utilization of anti-cancer medicines currently
deemed essential. Our findings have been used to make
suggestions for improved processes in order to better
manage patients with cancer in Kosovo given the limited
resources available. These findings will be followed up in
the future to help improve the care of these patients despite
the likely continued limited resources in Kosovo.
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